Angiogenesis, or the sprouting of new blood vessels from existing ones, occurs during development and in diseases such as diabetic retinopathy, endometriosis, psoriasis, rheumatoid arthritis, and tumor-induced angiogenesis ( 1 ) . Vascular endothelial cells rely on signaling from multiple integrins during the angiogenic process (for review see reference 2 ), including the ␣ v ␤ 3 and ␣ v ␤ 5 integrins; signaling by the ␣ v ␤ 3 and ␣ v ␤ 5 integrin leads to endothelial cell proliferation, migration, matrix metalloprotease activation, and resistance to apoptosis ( 3 ) .
The ␣ v ␤ 3 and ␣ v ␤ 5 integrins are subject to regulation during angiogenesis. Fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), two potent angiogenic factors released by tumors, induce the expression of these two integrins that collaborate with the FGF and VEGF receptors in angiogenic signaling pathways ( 4 ); disrupting angiogenic signaling by inactivation of either integrin or growth factor receptor leads to endothelial cell apoptosis ( 5 ) . The integrins are often up-regulated on metastatic tumors as well, leading to enhanced invasion, proliferation, and tumor survival ( 6 -9 ) by largely the same mechanisms operative in endothelial cells. For these reasons, the integrins and their regulatory mechanisms are attractive targets for the development of therapeutic drugs. Drugs that are currently being tested range from inhibitory integrin antibodies (e.g., Vitaxin [ 10 ] , based on the inhibitory antibody LM609 [ 11 ] ), to cyclic RGD peptides that interfere with ligand binding (e.g., cRGDfV, cilengitide, and ST1646 [ 12 -15 ] ), to peptidomimetics based on the RGD sequence (e.g., S247 [ 16 ] ). These inhibitors have all been shown to disrupt the growth of solid tumors as well as angiogenesis.
We have recently identifi ed a regulatory mechanism by which syndecan-1 (Sdc1), a cellsurface matrix receptor, regulates the activation of the ␣ v ␤ 3 and ␣ v ␤ 5 integrins on mammary carcinoma cells and fi broblasts ( 17 -20 ) . The syndecans are multifunctional extracellular matrix active site between amino acids 88 and 121 in its extracellular domain fail to rescue (see mSdc1 ⌬ 67 -121; Fig. 1 B ) .
We showed previously ( 20 ) that ␣ v ␤ 3 integrin activity is lost in MDA-MB-231 cell adhesion/spreading assays in the presence of soluble, recombinant glutathione S-transferasefused Sdc1 extracellular domain (GST-S1ED; ID 50 of ‫ف‬ 3 μ M). To test whether shorter peptides would mimic this activity, we derived a peptide spanning amino acids 82 -130 of mSdc1 ( Fig. 1 A ) . We call the inhibitory peptide sequence SSTN. Indeed, treatment of MDA-MB-231 cells with SSTN blocks their spreading on VN but not FN ( Fig. 1 C ) .
We hypothesize that S1ED or SSTN 82-130 may compete for an interaction between the S1ED and the ␣ v ␤ 3 integrin. To assess this, immunoprecipitations were performed using MDA-MB-231 cells expressing either empty vector (NEO), ectopic full-length mSdc1, or the mSdc1 ⌬ 67 -121 deletion mutant that lacks the active site. Immunoblotting reveals that the ␣ v ␤ 3 integrin coprecipitates with either native human Sdc1 (hSdc1) or ectopic mSdc1, yet fails to associate with the mSdc1 mutant bearing the ⌬ 67 -121 deletion ( Fig. 1 D ) . Coprecipitation is disrupted in the presence of either 30 μ M GST-S1ED protein (using either mS1ED or hS1ED to avoid reactivity with the precipitating mAb) or 3 μ M SSTN (which is not recognized by either precipitating mAb). These results suggest that these inhibitors block ␣ v ␤ 3 integrin activation by competitively displacing the integrin from an interaction with Sdc1.
To defi ne the minimal sequence required, we tested SSTN peptides (0 -100 μ M) carrying sequential N-and C-terminal deletions ( Fig. 2 C ) for their ability to block cell spreading on VN ( Fig. 2, A and B ) . The minimal peptide required for full activity is SSTN 92-119 . Deletion of two or three residues from either end of this peptide either diminishes (approximately threefold loss in activity in SSTN ) or completely abolishes (SSTN 94-119 and SSTN 88-116 ) activity. A peptide representing the homologous region of hSdc1, hSSTN , is equally effective as an inhibitor ( Fig. 2 C ) , confi rming that the active site is conserved between hSdc1 and mSdc1. Peptides displayed identical inhibitory eff ects on B82L fi broblasts, which rely solely on the ␣ v ␤ 5 integrin for adhesion and spreading on VN (unpublished data) ( 19 ) .
Sdc1 regulates the ␣ v ␤ 3 and ␣ v ␤ 5 integrins on vascular endothelial cells We next questioned whether the Sdc1 regulatory mechanism is operative on vascular endothelial cells. Human aortic endothelial cells (HAECs) and human dermal microvascular endothelial cells (HMEC-1s) express modest levels of Sdc1 and higher levels of ␣ v ␤ 3 and ␣ v ␤ 5 integrins ( Fig. 3 A ) . Mouse aortic endothelial cells (MAECs) express higher levels of Sdc1 than their human counterparts but less of the two integrins ( Fig. 3 A ) .
To determine if Sdc1 and the integrins are in a regulatory complex, immunoprecipitates from HMEC-1s were probed for the coprecipitation of ␤ 3 and ␤ 5 integrin subunits with Sdc1. Both integrins coprecipitate with the syndecan and receptors on the surface of all adherent cells ( 21 -23 ) . They anchor to the matrix via heparan sulfate (HS) glycosaminoglycan chains attached near the distal tips of their core proteins; these chains recognize " heparin-binding " domains present in most matrix ligands, including fi bronectin (FN), laminins, vitronectin (VN), thrombospondin, and the fi brillar collagens ( 21 ) . In addition, mounting evidence suggests that they assemble with and control the signaling of other cell surface receptors, including integrins. McFall et al. fi rst described a " cell-binding domain " in the extracellular domain of Sdc4 ( 24, 25 ) ; this site has recently been shown to regulate ␤ 1-containing integrins on mesenchymal cells, although the exact integrin target and regulatory mechanism remain unknown ( 26, 27 ) . Recombinant Sdc2 extracellular domain alters adhesion mechanisms in colon carcinoma cells, suggesting that a regulatory site also exists in its extracellular domain ( 28, 29 ) . More recently, we have shown that Sdc1 is necessary for activation of the ␣ v ␤ 3 integrin on mammary carcinoma cells ( 17, 20 ) . Silencing Sdc1 expression, selective deletion of amino acids in its extracellular domain, or targeted competition with domain-specifi c antibodies or recombinant extracellular domain protein disrupts integrin activation and matrix recognition necessary for cell spreading and invasion. Similar activation of the ␣ v ␤ 5 integrin by Sdc1 occurs on B82L fi broblasts, which rely exclusively on this integrin for attachment to VN and FN ( 19 ) . These extracellular syndecan-specifi c regulatory sites are readily accessible to therapeutic drugs and may hold promise as targets for combating tumorigenesis and other diseases in which their regulated mechanisms play a role.
Given the importance of the ␣ v ␤ 3 and ␣ v ␤ 5 integrins in angiogenesis, we examined the possibility that Sdc1 regulates these integrins on vascular endothelial cells during tumorinduced angiogenesis. We found that Sdc1 is expressed by mouse and human endothelial cells in vitro, and is expressed during angiogenesis induced by FGF or VEGF in vitro and in vivo. We found that the ␣ v ␤ 3 and ␣ v ␤ 5 integrins associate with Sdc1 and that this association can be disrupted by a peptide called synstatin (SSTN) that is derived from the active site in the Sdc1 core protein. Furthermore, SSTN is an eff ective inhibitor of angiogenesis in vitro and in vivo, and of mammary carcinoma formation in nude mice. These results defi ne the Sdc1 regulatory mechanism as a critical component of the angiogenic and tumorigenic process. RESULTS SSTN peptide inhibits Sdc1-mediated activation of the ␣ v ␤ 3 integrin on mammary carcinoma cells MDA-MB-231 human mammary carcinoma cells rely on Sdc1 for activation of the ␣ v ␤ 3 integrin during their binding and spreading on VN ( 17, 20 ) . Integrin activity is abolished by silencing Sdc1 expression with human-specifi c small interfering RNA (siRNA) but can be rescued by expression of mouse Sdc1 (mSdc1; Fig. 1 B ) . Cell binding and spreading on FN, which utilizes the ␣ 5 ␤ 1 integrin, is unaff ected ( Fig. 1 B ) ( 20 ) . Although native mSdc1 rescues integrin activity, deletion mutants (summarized in Fig. 1 A ) ; note that none of these are recognized by the human-specifi c mAb used for precipitation ( Fig. 3 B ) . As expected, both the GST-mS1ED protein (but not GST alone) and the in seemingly equal proportions (quantifi ed via comparison to a whole-cell lysate standard curve; not depicted) suggestive of a 1:1 correspondence ( Fig. 3 B ) . The ␣ v ␤ 1 integrin, which is not regulated by Sdc1 ( 17, 19, 20 ) , fails to coprecipitate (unpublished data). Immunoprecipitations were , and mSdc1 is immunoprecipitated (using mAb 281.2) from cells transfected with full-length mSdc1 or the mSdc1 deletion mutant (mSdc1 ⌬ 67-121 ). Immunoprecipitations were conducted in the presence or absence of GST, GST-S1ED (mS1ED if precipitating hSdc1 and hS1ED for mSdc1 precipitation), or SSTN 82-130. Blots were probed for coprecipitation of ␤ 3 integrin subunit ( ‫ف‬ 105 kD) using Fire & Ice. Note the nonspecifi c band (*) that appears in all lanes, including the nonspecifi c IgG 1 isotype control precipitations. Sdc1 runs as a band at approximately 85 kD after treatment with enzymes to remove its glycosaminoglycan chains; the core protein is visualized on the blots using mAb 3G10, which detects HS attachment stubs remaining on either the hSdc1 or mSdc1 core protein. Results are representative of at least three independent experiments. for both cell types when Sdc1 expression is reduced by ‫ف‬ 90% ( Fig. 3 F ) . This is compared with combined treatment with 30 μ g/ml ␣ v ␤ 3 and ␣ v ␤ 5 function -blocking antibodies LM609 and P1F6 ( Fig. 3 F ) .
We next tested whether the SSTN peptides inhibit integrin activation on the endothelial cells. HMEC-1s were plated on hSdc1 antibody (mAb B-B4), to which the cells attach and spread ( Fig. 4 A ) . Our previous work using carcinoma cells showed that Sdc1 ligation by this method leads to integrin activation and cell spreading ( 17 ) , even in the presence of EDTA to block potential ligand binding by the integrin. Indeed, the ␣ v ␤ 3 and ␣ v ␤ 5 integrins become activated when the cells attach to B-B4, detected by staining the cells with the ligand-mimetic Fab WOW-1 ( Fig. 4 A ) ( 30 ) . However, treatment with either 0.5 μ M SSTN 82-130 or 30 μ g/ml ␣ v ␤ 3 and ␣ v ␤ 5 integrin function -blocking antibodies (used as a comparative control) prevents both cell spreading and recognition by WOW-1, indicating that SSTN 82-130 inhibits integrin activation. A similar experiment was conducted using suspended human umbilical vein endothelial cells (HUVECs) in which cell-surface Sdc1 is fi rst decorated with hSdc1-specifi c mAb B-A38 and then clustered by addition of a secondary antibody in the presence or active SSTN 82-130 and SSTN 92-119 effi ciently disrupt the Sdc1 -integrin interactions, whereas the inactive SSTN 94-119 is without eff ect.
To test whether Sdc1 interacts directly with the integrins ( Fig. 3 C ) , GST-mS1ED immobilized on glutathione beads was mixed in solution with 1 μ M purifi ed ␣ v ␤ 3 or ␣ v ␤ 5 integrin in the presence of 10 μ M competitive SSTN 92-119 or noncompetitive SSTN . The purifi ed integrins associate with S1ED, and their binding is competed by SSTN 92-119 but not by SSTN . In addition, SSTN 92-119 prelabeled with photoactivatable Sulfo-SBED cross-linker (see Materials and methods) binds and transfers biotin label to both the ␣ and ␤ subunits of purifi ed ␣ v ␤ 3 integrin, whereas no transfer is detected with SSTN 94-119 ( Fig. 3 D ) .
We next questioned whether the Sdc1 regulatory mechanism aff ects integrin activity on endothelial cells. Sdc1 expression was silenced in HMEC-1s using siRNA ( absence of SSTN . WOW-1 binding shows that clustering of Sdc1 activates the integrin, and this is prevented by the SSTN peptide ( Fig. 4 B ) .
Blockade of integrin activation with the SSTN peptides is also shown by disrupted cell attachment and spreading on VN. HMEC-1s are dependent on both integrins, as partial tive SSTN 94-119 is without eff ect even at 100 μ M, addition of either 5 μ M mS1ED, 0.5 μ M SSTN 82-130 , or 0.5 μ M SSTN 92-119 blocks spreading on VN as eff ectively as (if not better than) spreading is observed if one integrin is blocked (e.g., LM609 to block ␣ v ␤ 3 , or P1F6 to block ␣ v ␤ 5 ), but a complete block occurs in the presence of both antibodies ( Fig. 4 C ) . Although the inac- To test the importance of the Sdc1 regulatory mechanism during angiogenesis, we tested the activity of SSTN peptides in the in vitro mouse aortic ring outgrowth assay ( 33 ) and the in vivo mouse corneal pocket angiogenesis model ( 34 ) . The aortic outgrowth assay was used to quantify microvessel outgrowth from segments of mouse aorta explanted to collagen gels in the presence of either VEGF or FGF-2, and incubated in the presence of either recombinant mS1ED protein or SSTN peptides. Microvessels are observed growing out of the aortic explants over 7 d in response to VEGF, and this is blocked by increasing concentrations of SSTN or by an antibody (M9) that inhibits mouse ␣ v -containing integrins ( Fig. 6 A ) . Single cells observed to be migrating out from the explants in the presence of SSTN or the blocking antibody are likely to be fi broblasts and pericytes. Indeed, desmin staining shows that pericytes line up on the PECAM-positive microvessels in the absence of SSTN and continue to migrate out from the explant in a disorganized fashion when SSTN prevents the outgrowth of PECAM-positive endothelial cells ( Fig. 6 B ) .
Quantifi cation of vessel outgrowth shows that SSTN inhibits both VEGF-and FGF-stimulated outgrowth. Although some vessel outgrowth is observed in the absence of exogenous angiogenic agents, likely caused by VEGF released by the pericytes growing out from the explant ( 35 ), the outgrowth is greatly increased by supplementation with FGF-2 or VEGF ( Fig. 6, C and D ) . Addition of recombinant S1ED blocks VEGF-induced outgrowth by > 70% at 10 μ M and > 95% at 30 μ M ( Fig. 6 C ) . FGF-induced outgrowth ( Fig. 6 D ) requires slightly higher inhibitory concentrations ( ‫ف‬ 30 μ M mS1ED for 70% inhibition). In comparison, SSTN 82-130 and SSTN 92-119 are 10 -30-fold more potent that mS1ED and show equivalent inhibition of VEGF-or FGF-induced outgrowth, displaying an ID 50 of ‫ف‬ 0.1 μ M. These concentrations are nearly identical to the ID 50 ' s displayed in the in vitro cell attachment and spreading assays with HMEC-1s and HAECs (compare with Fig. 4 ) and are comparable to the eff ects of 10 μ g/ml of the function-blocking ␣ v integrin mAb M9, which inhibits the activity of both the ␣ v ␤ 3 and ␣ v ␤ 5 integrins ( Fig. 6 ) .
The SSTN peptides were also tested in the in vivo corneal angiogenesis assay ( Fig. 7 ) . Poly(2-hydroxyethyl methacrylate) (Poly-HEMA) pellets containing 67 ng FGF-2 and 250 ng sucralfate (used as a slow-release agent) were implanted into the avascular mouse cornea. After 7 d, fl uorescent dextran was injected retroorbitally to highlight the vascular system at the time of sacrifi ce. Visual inspection of either the eye or the dissected cornea shows signifi cant vessel growth toward the implanted pellet from the margin of the cornea. To test the eff ects of blocking Sdc1, SSTN peptides were delivered systemically via Alzet osmotic pumps (see Materials and methods). Pumps the combined antibody treatment ( Fig. 4 B ) . Attachment and spreading on FN is not aff ected by these peptides ( Fig. 4 C ) or by the integrin blocking antibodies (unpublished data). Quantifi cation of these results shows that competition with mS1ED at 1 -3-μ M concentrations reduces HMEC-1 cell spreading on VN by > 80 -90% ( Fig. 4 D ) , with an ID 50 of ‫ف‬ 1 μ M for HAECs, which are more resistant than the HMEC-1s. In comparison, SSTN 82-130 and SSTN 92-119 display an equivalent inhibitory activity when used at a 10-fold lower concentration, displaying signifi cant inhibitory properties in the 0.1 -0.3-μ M range. As observed in Fig. 4 C , cell adhesion is also disrupted at the higher inhibitory concentrations and can be prevented altogether by adding increased concentrations of the peptides (unpublished data).
Lastly, the specifi city of the SSTN peptides for this Sdc1-regulated mechanism was demonstrated comparing HUVECs that are either positive or negative for Sdc1 expression. Although primary HUVECs do express Sdc1 (Sdc1 + ), one isolate of these cells that we obtained failed to express the proteoglycan (Sdc1 Ϫ ), as shown by fl ow cytometry ( Fig. 4 E , left) ; both the Sdc1 + and Sdc1 Ϫ cells express identical levels of ␣ v ␤ 3 and ␣ v ␤ 5 integrins. Somewhat surprisingly, both sets of cells attach and spread on VN ( Fig. 4 E , right) , both are inhibited by mAb LM609, and both are inhibited further by addition of mAbs LM609 and P1F6 to block both ␣ v ␤ 3 and ␣ v ␤ 5 integrins. Addition of SSTN 82-130 inhibits the spreading of the Sdc1 + HUVECs, similar to its eff ect on HMEC-1s and HAECs, but is without eff ect on the Sdc1 Ϫ HUVECs. Similarly, silencing Sdc1 expression on the Sdc1 + HUVECs blocks their spreading, whereas the siRNA is without eff ect on the Sdc1 Ϫ cells, as would be expected. This suggests that an alternative activation mechanism exists in the absence of Sdc1 gene expression, and that the SSTN peptide is specifi c only for the Sdc1-regulated ␣ v ␤ 3 and ␣ v ␤ 5 activation mechanism.
SSTN inhibits angiogenesis in vitro and in vivo
As a fi rst step in understanding a potential role for Sdc1 in angiogenesis in vivo, we questioned whether Sdc1 was expressed either in the endothelial lining of resting blood vessels (using the mouse aorta) or in microvessels arising from the aorta in response to angiogenic stimuli. As we found when examining the MAEC line in culture ( Fig. 3 A ) , both Sdc1 and the ␣ v ␤ 3 and ␣ v ␤ 5 integrins are present even on the resting mouse aorta ( Fig. 5 A ) . In addition, microvessels growing out from mouse aortic explants over 7 d in response to FGF-2 stain positively for Sdc1, which appears coexpressed with the ␣ v ␤ 3 and ␣ v ␤ 5 integrins ( Fig. 5 B ) . In addition, Sdc1 expression is observed in activated endothelial cells of mouse tumor vasculature ( Fig. 5 C ) . Tumors derived from Wnt-1 overexpression ( 31 ) in the mammary gland show a high degree of vascularization, identifi ed as internal networks lined by a thick cell layer that stains intensely for Sdc1 and for platelet -endothelial cell adhesion molecule -1 (PECAM-1/ CD31), indicative of activated endothelium. In fact, Sdc1 expression in these cells swamps out the positive staining for Sdc1 seen in the mammary epithelial cells, which are known We also tested SSTN peptide on male BALB/c Sdc1 knockout mice, as it has been previously reported that angiogenesis is not blocked in this animal ( 36 ) . Indeed, we found that Sdc1 Ϫ / Ϫ mice display corneal vessel outgrowth in response to FGF-2 ( Fig. 7 C , right, blue bars) . In addition, this vessel outgrowth is reduced > 60% by circulating cRGDfV, a cyclic RGD inhibitory peptide specifi c for ␣ v integrins, compared with an inactive cRADfV peptide. This duplicates the extent of inhibition observed for this RGD peptide in other mouse models ( 15, 37 ) . However, the angiogenesis is not blocked by as much as 100 μ M SSTN 82-130 ; this concentration of SSTN 82-130 inhibits angiogenesis by 90% in a parallel delivering 1 μ l/h of up to 100 μ M SSTN 82-130 or SSTN 92-119 achieved a nearly total block of angiogenesis, with an ID 50 of ‫ف‬ 3 -10 μ M ( Fig. 7 A ; and Fig. 7 C , left) . To correlate this with the active concentration in the plasma, we took advantage of rabbit polyclonal antibodies generated against mS1ED that detect active SSTN on dot blots ( Fig. 7 B ) . This shows that SSTN accumulates to 125 -150 nM in the blood after 1 wk of treatment with 10 μ M SSTN. This correlates well with the ID 50 of ‫ف‬ 100 nM observed in vitro and suggests a clearance rate of 10 -13 h in the plasma. In contrast, delivery of 100 μ M of the inactive SSTN 88-116 or SSTN 94-119 in Alzet pumps has no eff ect on vessel outgrowth ( Fig. 7 A ; and Fig. 7 C , left) . results in a signifi cant reduction in tumor size relative to control mice ( Fig. 8, A and B ) . Moreover, staining the tumor sections for PECAM-1 or desmin shows a signifi cant reduction in the number of tumor vessels in the SSTN-treated tumors; both endothelial cells and pericytes are observed, but in reduced numbers of vessels ( Fig. 8 C ) . Quantifi cation of angiogenesis either by measuring total vessel length in the sections or total PECAM-1 positive staining shows an 11-fold reduction in animals bearing pumps containing 400 μ M SSTN ( Fig. 8 D ) .
DISCUSSION
Previous work described a dependence on Sdc1 for activation of the ␣ v ␤ 3 and ␣ v ␤ 5 integrins. This raises the question experiment with wild-type BALB/c mice ( Fig. 7 C , right,  red bars) . Thus, a compensatory mechanism exists for the activation of the ␣ v ␤ 3 and ␣ v ␤ 5 integrin in the Sdc1 Ϫ / Ϫ mouse that is insensitive to the inhibitory SSTN peptide.
Finally, SSTN 82-130 was tested in an in vivo orthotopic tumor model ( Fig. 8 ) . MDA-MB-231 human mammary carcinoma cells were injected subcutaneously into female, athymic BALB/c nude mice. Palpable tumors were allowed to form for 1 wk after injection, at which time Alzet pumps delivering 0. 25 of whether this regulatory mechanism exists on the vascular endothelium during angiogenesis. Although expression of Sdc1 in the vascular endothelium has not been studied extensively, several reports indicate that it is expressed in the endothelium of newly formed vessels in wound granulation tissue ( 38 -41 ) and the endothelial lining of intramyocardial blood vessels in the rat heart ( 42 ); however, no expression is seen in blood vessels in unwounded skin ( 39 ) nor in the normal rabbit aorta ( 43 ) , suggesting that its expression may be regulated, perhaps by ephrin signaling ( 44 ) . A role in angiogenesis, however, is seemingly cast in doubt by the fi nding that angiogenesis is not impeded in the Sdc1-null mouse ( 36 ) .
Our fi ndings suggest that Sdc1 is indeed expressed in the vascular endothelium and that its core protein has an important regulatory role during the angiogenic process. It is detected, along with the ␣ v ␤ 3 and ␣ v ␤ 5 integrins, in cultured MAECs, in resting mouse aorta, and in angiogenic aortic microvessels in vitro and tumor vasculature in vivo. Although we have not investigated directly whether or not Sdc1 expression is up-regulated during angiogenesis, it does display intense staining in the endothelial cells undergoing angiogenesis in the aortic ring outgrowth assay and in mammary tumors. Up-regulated expression of Sdc1 would mimic that of the ␣ v ␤ 3 integrin, which displays low or nonexistent expression in most adult tissues and is dramatically up-regulated in the vascular endothelium during angiogenesis ( 45 -47 ) . Most importantly, blocking Sdc1 expression or competitively blocking its interaction with these integrins using SSTN serves to inactivate the integrins and block endothelial cell attachment, spreading, and invasion/outgrowth in vitro, as well as angiogenesis and tumor growth in vivo. The regulatory mechanism remains unknown, but it appears to rely on a direct interaction between the integrins and Sdc1.
Interestingly, our fi ndings do confi rm the ability of the Sdc1-null mouse to mount a seemingly normal angiogenic response, a response that appears dependent on the ␣ v ␤ 3 and ␣ v ␤ 5 integrins despite the absence of Sdc1. This fi nding is . The estimated concentration of SSTN in the serum is plotted versus its starting concentration in the pump (right). Data are representative of three independent experiments. (C) Quantifi cation of corneal angiogenesis in wild-type and Sdc1-null (Sdc1 Ϫ / Ϫ ) mice. Mean total vessel outgrowth in the presence or absence of SSTN (concentration in the pump is shown) is quantifi ed and expressed relative to the PBS control set at 100% ( ± SD). Wild-type and Sdc1 Ϫ / Ϫ mice (six mice per data point for each cohort from three independent experiments) were directly compared using treatments of 100 μ M SSTN . The Sdc1 Ϫ / Ϫ mice (three mice per data point for one experiment) were also treated with 22.7 mM ␣ v integrin -specifi c cRGDfV inhibitory peptide or inactive cRADfV peptide. Data are presented as means ± SEM. *, P < 0.05; **, P < 0.01.
matched by an isolate of HUVECs that are also Sdc1 negative. They display active ␣ v ␤ 3 and ␣ v ␤ 5 integrins, but unlike their Sdc1-positive counterparts, they are not dependent on Sdc1 and are unaff ected by SSTN. In these Sdc1-negative cells (and in the Sdc1-null mice), integrin activation presumably occurs via a compensatory mechanism that is activated in the absence of Sdc1 gene expression. This not only explains why angiogenesis is observed in the Sdc1-null mouse, but it also provides a strong argument for the specifi city of the SSTN peptide. That is, the peptide appears to compete for a specifi c interaction of Sdc1 with these integrins that is essential for their activation on Sdc1-expressing cells. If this mechanism is absent, the peptide has no apparent off -target eff ects even at concentrations up to 100-fold greater than its ID 50 .
Although the mechanisms of integrin activation have received considerable scrutiny, especially during processes such as platelet activation and in angiogenesis, the reliance of the ␣ v ␤ 3 and ␣ v ␤ 5 integrins on Sdc1 during angiogenesis has not been appreciated until now. The ␣ v ␤ 3 integrin has been shown previously to associate with other membrane proteins, with some leading to enhanced activation of the integrin ( 48 ) . Integrin-associated protein (also known as CD47) presents an intriguing comparison to Sdc1 in that it associates with the ␣ IIb ␤ 3 and ␣ v ␤ 3 integrins via its extracellular domain, and this interaction alone is suffi cient to activate these integrins ( 49, 50 ) .
The activation of an integrin typically refers to a conformation change that dramatically increases ligand binding affi nity, and the ␣ IIb ␤ 3 and ␣ v ␤ 3 integrins have been used as models to begin to understand the activation mechanism. It proceeds through two or more activation states, each resulting in a conformational change in the integrin ' s extracellular domain in response to intracellular signals and extracellular ligand binding ( 51 -55 ) . In a current model for ␣ v ␤ 3 activation, the inactive integrin is in a bent confi guration and opens like a switchblade when activated ( 56 ) . This occurs in response to talin binding to the ␤ 3 integrin cytoplasmic domain and breaking of the salt bridge that maintains the inactive conformation ( 57, 58 ) . However, it is also enhanced by oligomerization of the integrin subunits within the plane of the plasma membrane ( 59 ) , and by extracellular interactions with matrix ligands and/or other membrane proteins ( 48 ) .
Our data now suggest that the active conformation of the ␣ v ␤ 3 and ␣ v ␤ 5 integrins is favored by their direct association with Sdc1. The integrins are activated by plating endothelial cells on Sdc1 antibody, or by antibody-induced clustering of Sdc1 on suspended endothelial cells, as shown in this study by the binding of the ligand-mimetic Fab WOW-1; this has also been shown with carcinoma cells ( 20 ) . The activation that occurs when Sdc1 is engaged by antibody is not blocked by depletion of divalent cations that are otherwise necessary for Control, Atlanta, GA) and T.J. Lawley (Emory University, Atlanta, GA) ( 67 ) . HUVECs were obtained from Cambrex Life Sciences Corp. Human endothelial cells were cultured in MCDB-131 (Invitrogen) medium supplemented with 5 mM l-glutamine, 20 mM NaHCO 3 (Sigma-Aldrich), 10 ng/ml epidermal growth factor, 1 μ g/ml hydrocortisone, bovine brain extract with heparin and antibiotics (SingleQuot kit; Cambrex Life Sciences Corp.), and 15% FBS (Gemini Bio-Products).
Cell attachment and spreading assay. Cell attachment and spreading assays on Sdc1-specifi c antibody or VN and silencing of Sdc1 expression by siRNA were conducted as previously described ( 19, 20 ) . Silencer control siRNAs (Applera Corporation) were use for control siRNA transfections. Images were acquired using an objective (PlanFluor 10 × [0. Construction of mSdc1 mutant. The mSdc1 ⌬ 67-121 mutant was constructed by digesting full-length mSdc1 cDNA (pcDNA3; provided by R. Sanderson, University of Alabama at Birmingham, Birmingham, AL) with BmgBI and BstEII. The BstEII overhang was then fi lled in using the Klenow DNA polymerase fragment (Promega) and the vector then bluntend ligated using T4 DNA ligase (New England Biolabs, Inc.). The mutant was transfected into MDA-MB-231 cells using LipofectAMINE PLUS (Invitrogen) and 10 μ g of plasmid, in accordance with the manufacturer ' s instructions. A stable population (100 -300 colonies) was selected in 1.5 mg/ml G418 (EMD) and comparatively sorted against cells expressing fulllength mSdc1 for equal expression levels by fl ow cytometry using mAb 281.2 under sterile conditions on a triple-laser FACSVantage SE equipped with a FACSDiva digital electronics analyzer (BD).
Flow cytometry. Cells were scanned at the University of Wisconsin Comprehensive Cancer Center Flow Cytometry Facility using a benchtop cytometer (FACSCalibur; BD Biosciences). For cell-surface staining of Sdc1 and/or integrins, cells were lifted in Tris-buff ered saline (TBS) containing 5mM EDTA (TES), washed in HEPES-buff ered DMEM (Hb-DME) containing 10% serum, incubated for 1 h on ice with 1 μ g of primary antibody per 5 × 10 5 cells, washed, and counterstained with Alexa Fluor 488 -conjugated secondary antibodies (Invitrogen). Cell scatter and propidium iodide (1 μ g per sample; Sigma-Aldrich) staining profi les were used to gate live, single-cell events for data analysis. For WOW1 Fab staining (i.e., detection of activated ␣ v ␤ 3 integrin), HUVECs were lifted in TES and washed in serum-free medium (Hb-DME containing 0.1% heat-denatured BSA [hdBSA]); this medium was used for all washes and incubations that follow unless otherwise specifi ed. To cluster Sdc1, suspended cells were incubated with 1 μ g/ml of mAb B-A38 per 5 × 10 5 cells (or mIgG1 as an isotype control) for 15 min at 37 ° C, washed, and incubated with 5 μ g/ml goat anti -mouse IgG secondary antibody (Jackson ImmunoResearch Laboratories) for an additional 15 min. Cells were washed and blocked for 15 min in serum-free medium containing 1% hdBSA and a 1:100 dilution of monovalent Fab fragment of goat antimouse IgG. Cells were washed with a stoichiometric excess of serum-free medium and incubated with WOW-1 Fab (1:4 dilution) for 30 min at 37 ° C in the presence or absence of 1 μ M SSTN . Cells were washed with serum-free medium, fi xed in 4% paraformaldehyde (PFA) for 30 min, and quenched in 0.1 M glycine (in PBS) for 15 min. Cells were then counterstained with 10 μ g/ml Alexa Fluor 488 -conjugated goat anti -mouse IgG secondary antibody (Invitrogen) before scanning. Mean fl uorescent intensity of triplicate samples was used as a measure of activated ␣ v ␤ 3 integrin.
Immunoprecipitations. mSdc1 and hSdc1 were immunoprecipitated using mAbs 281.2 and B-B4, respectively. 3 -5 × 10 6 cells per milliliter were washed and lysed in buff er containing 50 mM HEPES (pH 7.4), 150 mM NaCl, 10 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, and a 1:100 dilution of protease inhibitor cocktail set III (EMD) for 20 min on ice. Insoluble cell debris was removed by centrifugation at 20,000 g for 15 min at 4 ° C. Cell ligand binding by the integrin, indicating that Sdc1 is engaged as a membrane coreceptor, not as a ligand. The fact that WOW-1 is a monovalent Fab indicates that the activation is a true increase in integrin affi nity rather than increased avidity. As we now show that the syndecan and ␣ v ␤ 3 and/or ␣ v ␤ 5 integrins form a complex, likely via lateral interactions of their extracellular domains, it seems apparent that clustering Sdc1 leads to clustering of the integrins as well. It is possible that the clustering brings together kinases associated either with the integrin or the Sdc1, initiating kinase transphosphorylation and activation of signaling pathways that activate the integrin through talin. In vivo, clustering would be envisioned to take place when Sdc1 engages the heparin-binding domains of multivalent matrix ligands. SSTN appears to inhibit tumorigenesis and angiogenesis by displacing Sdc1 from the integrins and, thus, blocking their activation during this clustering event.
MATERIALS AND METHODS

Materials.
Sdc1-specifi c antibodies used were mouse mAbs B-B4 and B-A38 (hSdc1; AbD Serotec) and rat mAb 281.2 (mSdc1) ( 60 ) . Rabbit polyclonal antibodies against recombinant mS1ED were affi nity purifi ed as previously described ( 20 ) and used to detect SSTN. Mouse mAb 3G10, which specifi cally recognizes terminal unsaturated uronic acid residues that remain on the core protein after treatment with heparin lyases ( 61 ), was used for simultaneous detection of mSdc1 and hSdc1 on Western blots. Integrin antibodies include the polyclonal antibodies AB1923, AB1932, and AB1926 (against ␣ v , ␤ 3 , and ␤ 5 , respectively; Millipore) and mAb N29 (used for Western blotting for ␤ 1 ; Millipore); blocking mAbs P1F6 and M9 (for Mouse mammary tumors were provided by C. Alexander (University of Wisconsin-Madison, Madison, WI); tumors were from mice overexpressing Wnt-1 under control of the MMTV-LTR ( 31, 62 ) or from FVB MMTV -⌬ N89 ␤ -catenin transgenic mice ( 63 ) . Tumors were embedded in optimum cutting temperature (OCT) compound (VWR) and frozen sections were prepared for staining.
The SSTN peptides (80 -90% pure) were purchased from GenScript Corporation. They are based on the mSdc1 sequence. Recombinant mS1ED fusion protein was prepared as previously described ( 20 ) .
Type-I collagen was purifi ed from rat tail tendons ( 64 ) , solubilized in 0.1 M acetic acid, and dialyzed against 0.1 × DMEM (no serum) at pH 4 to remove the acetic acid. VN was purifi ed from human plasma using a previously described method ( 65 ) .
Cell culture. All cell lines were cultured at 37 ° C in 92.5% air/7.5% CO 2 . MDA-MB-231 human mammary carcinoma cells and MAECs were grown in DMEM (Thermo Fisher Scientifi c) supplemented with 10% FCS (Thermo Fisher Scientifi c), 4 mM l-glutamine (Sigma-Aldrich), and 100 U/ml penicillin and 100 μ g/ml streptomycin (Invitrogen). MAECs and HAECs were provided by R. Auerbach (University of Wisconsin-Madison, Madison, WI). These are spontaneously immortalized cell lines identifi ed as endothelial by phenotypic markers ( 66 ) . SV40-T immortalized HMEC-1s were developed and provided by E.W. Ades and F.J. Candal (Center for Disease
